VALIRX PLC

• ⚠

  Material uncertainty over going concern

  Should future fund raisings be unsuccessful, this may cast significant doubt on the Group and parent Company's ability to continue as a going concern.

1. VALIRX PLC 2006-10-03 → present
2. AZURE HOLDINGS PLC 2003-11-27 → 2006-10-03
3. ROOM SERVICE GROUP PLC 2002-01-08 → 2003-11-27
4. THE CUBE8 GROUP PLC 2001-06-14 → 2002-01-08
5. CUBE8.COM PLC 2000-01-26 → 2001-06-14

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Adler Shine LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Should future fund raisings be unsuccessful, this may cast significant doubt on the Group and parent Company's ability to continue as a going concern.”

Group structure

1. VALIRX PLC · parent
   1. ValiRx Bioinnovation Limited 100% · England & Wales · Intermediate holding company
   2. ValiPharma Limited 100% · England & Wales · Therapeutic research & development
   3. Valisrc Limited 100% · England & Wales · Dormant
   4. ValiSeek Limited 55.55% · England & Wales · Therapeutic research & development
   5. Cytolytix Limited 60% · England & Wales · Therapeutic research & development
   6. Inaphaea Biolab Limited 100% · England & Wales · providing laboratory facilities to the ValiRx Group and offering products and services associated with patient derived cells

Significant events

• “The Company terminated the exclusivity Letter of Intent with TheoremRx Inc by mutual agreement. The termination of the LOI followed notification by TheoremRx of a decision not to proceed with an amendment to the LOI to return the territory of Taiwan and maintain exclusivity in exchange for a non-refundable payment of $200,000 by 31 March 2025. As a consequence, the Company intends to move VAL201 to a prostate cancer focussed special purpose vehicle and will file new IP to extend the patent life.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

5

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +418.5%

  £9,600 → £49,775

• Cash

  +790.7%

  £174,684 → £1,555,986

• Net assets

  +34.8%

  £2,903,927 → £3,915,693

• Employees

  -12.5%

  16 → 14

• Operating profit

  +6.8%

  -£2,298,539 → -£2,141,671

• Profit before tax

  +7.5%

  -£2,302,958 → -£2,130,455

• Wages

  -0.3%

  £734,022 → £731,636

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers